Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model.
Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid points when defending their stance. Sure, the price tag may look like a steal, but the fact that shares are trading at such low levels could reflect overwhelming headwinds or weak fundamentals.
That being said, the fans offer up a solid argument as well. Not only does the low price mean you get more shares for your money, but hefty returns are also on the table. Even seemingly insignificant share price appreciation can result in colossal percentage gains that other more well-known or expensive names aren’t as likely to deliver.
The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps?
To help with the due diligence process, we used TipRanks’ database to zero in on only the penny stocks that have received bullish support from the analyst community. We found two that are backed by enough analysts to earn a “Strong Buy” consensus rating. Not to mention each offers up massive upside potential and could climb to $17 or even higher.
AlloVir, Inc. (ALVR)
We’ll start with AlloVir, a clinical-stage biopharma company working on new allogenic, virus-specific T cell therapies (VSTs) to target a range of dangerous viral diseases with high unmet medical needs. The company’s drug candidates are developed on a proprietary platform and are designed as off-the-shelf VSTs to restore patients’ immunity and act as treatments or preventative therapies.
Story continues
The most advanced of AlloVir’s drug candidates has…
..